Celebra 100 mg Norge - norsk - Statens legemiddelverk

celebra 100 mg

upjohn eesv - celekoksib - kapsel, hard - 100 mg

Celebra 200 mg Norge - norsk - Statens legemiddelverk

celebra 200 mg

upjohn eesv - celekoksib - kapsel, hard - 200 mg

Celebrex 200 mg Norge - norsk - Statens legemiddelverk

celebrex 200 mg

2care4 aps - celekoksib - kapsel, hard - 200 mg

Celebrex 200 mg Norge - norsk - Statens legemiddelverk

celebrex 200 mg

orifarm as - celekoksib - kapsel, hard - 200 mg

Celebrex 100 mg Norge - norsk - Statens legemiddelverk

celebrex 100 mg

orifarm as - celekoksib - kapsel, hard - 100 mg

Celebrex 200 mg Norge - norsk - Statens legemiddelverk

celebrex 200 mg

2care4 aps - celekoksib - kapsel, hard - 200 mg

Celebrex 100 mg Norge - norsk - Statens legemiddelverk

celebrex 100 mg

2care4 aps - celekoksib - kapsel, hard - 100 mg

Celebra 200 mg Norge - norsk - Statens legemiddelverk

celebra 200 mg

farmagon - celekoksib - kapsel, hard - 200 mg

Celebra 200 mg Norge - norsk - Statens legemiddelverk

celebra 200 mg

farmagon - celekoksib - kapsel, hard - 200 mg

Sutent Den europeiske union - norsk - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.